Opdivo®

Understanding Opdivo® 

Opdivo® (nivolumab) is a checkpoint inhibitor immunotherapy used to treat various types of cancer by enhancing the immune system’s ability to recognize and attack cancer cells. It works by blocking the PD-1 receptor on T cells, preventing cancer cells from evading immune detection. This activation of the immune system allows it to identify and destroy tumors more effectively.

How Opdivo® Works:

• Blocks PD-1, a checkpoint receptor that helps cancer cells evade immune attacks.
• Boosts T-cell activity, enabling the immune system to detect and destroy tumors.
• Enhances immune response, helping fight cancer more effectively.

FDA Approval:

• Opdivo® (nivolumab): Initially approved in July 2014 for advanced melanoma, with subsequent approvals expanding its use to treat many other cancers.

For more information, please visit the Opdivo® patient website and speak with your healthcare provider to determine if Opdivo® is the right treatment option for you.